Q32 Bio
QTTB
54 hedge funds and large institutions have $60.6M invested in Q32 Bio in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 8 closing their positions.
127% more capital invested
Capital invested by funds: $26.7M → $60.6M (+$34M)
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
4% more funds holding
Funds holding: 52 → 54 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.92% less ownership
Funds ownership: 65.37% → 64.46% (-0.92%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.95M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$1.17M |
| 3 |
MCM
Monimus Capital Management
Woodbridge,
New Jersey
|
+$638K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$590K |
| 5 |
Renaissance Technologies
New York
|
+$510K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Acorn Capital Advisors
New York
|
-$847K |
| 2 |
P
Pfizer
New York
|
-$837K |
| 3 |
Millennium Management
New York
|
-$170K |
| 4 |
MAM
Monaco Asset Management
Monaco
|
-$169K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$144K |
QTTB Hedge Fund Activity: Q1 2026 in Review
54 of the 8,205 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q1 2026, worth a combined $60.6M — up 127% from $26.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new QTTB positions and 8 closed out — a net gain of 4 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Opaleye Management, adding an estimated $4.95M. The largest seller was Acorn Capital Advisors, cutting an estimated $847K.
- 54 institutional investors held Q32 Bio (QTTB) as of Q1 2026, up from 52 in Q4 2025.
- Funds reported $60.6M of Q32 Bio stock for Q1 2026, up 127% quarter-over-quarter.
- 12 funds opened new Q32 Bio positions in Q1 2026 and 8 closed out, a net change of +4 holders.
- The largest Q32 Bio buyer in Q1 2026 was Opaleye Management, an estimated $4.95M added.
- The largest Q32 Bio seller in Q1 2026 was Acorn Capital Advisors, an estimated $847K sold.
Based on aggregated 13F filings for Q1 2026.